EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Preservation of sexual function with Optilume—a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia

Olivia Copelan iD, Jared Moss, Sheldon Freedman, Karl Coutinho, Dean Elterman, Jeffrey Marotte, Osvaldo Padron, Neal Shore, Jeffrey Spier, Jed Kaminetsky, Brian Mazzarella, Alexis Te und 2 weitere

The Journal of Sexual Medicine · 2025

DOI: 10.1093/jsxmed/qdae206 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Olivia Copelan und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Men's Health Stritch School of Medicine, Maywood, IL 60153, United States. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Sexual Dysfunction, Physiological, Dilatation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms.

Aim

We now assess the impact of Optilume BPH procedure on sexual function.

Methods

Prior published results have described the methods of data collection during the PINNACLE study, which demonstrated durable improvement in urinary symptoms. Follow-up assessments for the current study included IIEF-EF and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD). Semen quality was also examined. Outcomes IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3 months, 6 months, or 12 months.

Results

A total of 148 men were randomized to receive the procedure (100) or a sham surgical procedure (48). Subjects in both groups had similar rates of erectile dysfunction (ED) previously diagnosed at baseline (56% vs 54.2%, P = .83) and those men who were sexually active. IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3, 6, or 12 months. Change in IIEF-EF scores remained consistent across all levels of baseline ED severity after Optilume BPH procedure. No clear trend was seen after treatment with Optilume BPH for semen volume, sperm motility, progressive motility, or sperm morphology. Clinical Implications The Optilume BPH catheter system provides patients with a durable improvement in lower urinary tract symptoms while preserving sexual function. Strengths and limitations This study uses validated questionnaires to assess patients’ sexual function at baseline and regularly for 1 year after the procedure. Given exclusion criteria regarding patient age and prostate size, the results may not be applicable to all BPH phenotypes.

Conclusion

Optilume appears to provide clinical benefit with a high degree of patient satisfaction and minimal impact on sexual function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaLower Urinary Tract SymptomsSexual Dysfunction, PhysiologicalDilatationHumansMaleMiddle AgedAgedErectile DysfunctionSurveys and QuestionnairesTreatment OutcomeEjaculationSemen Analysis

Stichwörter der Autor:innen

benign prostatic hyperplasia (BPH)ejaculatory functionerectile functionlower urinary tract symptoms (LUTS)prostaterandomized controlled trial (RCT)sexual function

Autor:innen und Institutionen

  • The Center for Men's Health Stritch School of Medicine, Maywood, IL 60153, United States.
  • Oschner LSU Health, Shreveport, LA 60153, United States.
  • Sheldon Freedman Urology, Las Vegas, NV 60153, United States.
  • New Jersey Urology LLC, Millburn, NJ 60153, United States.
  • University of Toronto, Toronto, ON 60153, Canada.
  • Arkansas Urology, Little Rock, AR 60153, United States.

ORCID-Profile: Olivia Copelan

Zitieren

APA

Copelan, O., Moss, J., Freedman, S., Coutinho, K., Elterman, D., Marotte, J., Padron, O., Shore, N., Spier, J., Kaminetsky, J., Mazzarella, B., Te, A., Kaplan, S. A., & McVary, K. T. (2025). Preservation of sexual function with Optilume—a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdae206

Vancouver

Copelan O, Moss J, Freedman S, Coutinho K, Elterman D, Marotte J, et al. Preservation of sexual function with Optilume—a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdae206

BibTeX
@article{Copelan2025,
  author = {Copelan, Olivia and Moss, Jared and Freedman, Sheldon and Coutinho, Karl and Elterman, Dean and Marotte, Jeffrey and Padron, Osvaldo and Shore, Neal and Spier, Jeffrey and Kaminetsky, Jed and Mazzarella, Brian and Te, Alexis and Kaplan, Steven A and McVary, Kevin T},
  title = {Preservation of sexual function with Optilume—a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia},
  journal = {The Journal of Sexual Medicine},
  year = {2025},
  doi = {10.1093/jsxmed/qdae206}
}
Kostenlos starten →